Adverse effects of lumbar myelography with amipaque and dimer-X.

Abstract

The adverse effects in a series of 50 lumbar myelographies with Amipaque were compared with those in a corresponding series, examined with Dimer-X. Side effects occurred in 58% of the cases examined with Amipaque and in 68% of the Dimer-X series. No seizures occurred in 58% of the cases examined with Amipaque and in 68% of the Dimer-X series. No seizures occurred in either series but slight fibrillations of fasciculations appeared in 2 Dimer-X patients. Hyperreflexia of the legs was recorded in 22% of the Amipaque and in 36% of the Dimer-X cases. Other adverse reactions to the media were mild to moderate. Some burst activity, but no definite paroxysmal abnormality was noted in EEG recordings in 2 Amipaque cases. The low epileptogenicity of Amipaque has ensured a wider safety margin of lumbar myelography.

• Authors: L Irstam, U Selldén
• Journal: Acta radiologica: diagnosis (Acta Radiol Diagn (Stockh)) Vol. 17 Issue 2 Pg. 145-59 (Mar 1976) ISSN: 0567-8056 [Print] Sweden
• PMID: 1274652 (Publication Type: Journal Article)

Chemical References

• Iodobenzoates
• Iothalamic Acid
• Diazepam
• Metrizamide
• Iothalamate Meglumine

Topics

• Adult
• Aged
• Brain (drug effects)
• Diazepam (therapeutic use)
• Drug Evaluation
• Electroencephalography
• Female
• Fever (chemically induced)
• Headache (chemically induced)
• Humans
• Iodobenzoates (adverse effects)
• Iothalamate Meglumine (adverse effects)
• Iothalamic Acid (analogs & derivatives)
• Lumbosacral Region
• Male
• Metrizamide (adverse effects)
• Middle Aged
• Myelography
• Nausea (chemically induced)
• Pain (chemically induced)
• Premedication
• Seizures (chemically induced)